New STELFONTA® data presented at the 2023 Veterinary Cancer Society Annual Conference
Brisbane, 16 October 2023
QBiotics Group Limited (QBiotics) is pleased to share a poster presented at the 2023 Veterinary Cancer Society Annual Conference in Reno, Nevada, that showcases new data on QBiotics’ registered and marketed veterinary therapeutic, STELFONTA® (tigilanol tiglate).
The study explored the feasibility of obtaining viable tissue samples for histopathology, genomic analysis, and prognostic evaluation within 5 minutes of intratumoural administration of STELFONTA®. The study also evaluated whether collection of biopsy samples affected the efficacy of STELFONTA®.
Poster background
Conference: The 2023 Veterinary Cancer Society Annual Conference in Reno, Nevada from 12 to 14 October, 2023.
Title: Diagnostic viability of canine Mast Cell Tumour tissue biopsy samples acquired 5-10 minutes post-tigilanol tiglate treatment
Authors: Pamela D. Jones1, Graham K. Brown1, Kenneth Day2, William Hendricks2, Sharadha Sakthikumar2, Derick Whitley2
The Veterinary Cancer Society Annual Conference is a key event for both the veterinary community and for showcasing our most recent STELFONTA® data. QBiotics collaborated with Vidium Animal Health to conduct the study, which yielded some important findings. Biopsy within 5-10 minutes post-tigilanol tiglate provides viable tissue samples for histopathological and genomic diagnostics without compromising treatment efficacy.
STELFONTA® is marketed in Europe, the United Kingdom, the USA and Australia by QBiotics’ distribution and marketing partner Virbac, a global animal health company.
A copy of the poster presentation can be viewed here.
- QBiotics Group Limited
- Vidium Animal Health
FURTHER INFORMATION
DR VICTORIA GORDON, CEO & MANAGING DIRECTOR, QBIOTICS GROUP
communications@qbiotics.com or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ business model is to develop products that have applications in both veterinary and human markets. Success in the veterinary programme validates QBiotics technology and informs the early stages of human development, while having the potential to generate early revenue.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.